Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
// Wei Xia Ang 1, 2, * , Zhendong Li 1, * , Zhixia Chi 1 , Shou-Hui Du 1 , Can Chen 3 , Johan C.K. Tay 1 , Han Chong Toh 4 , John E. Connolly 5 , Xue Hu Xu 6 , Shu Wang 1, 2 1 Department of Biological Sciences, National University of Singapore 117543, Singapore 2 Institute of Bioengineering and Nanotechnology 138669, Singapore 3 Tessa Therapeutics, Pte Ltd., 239351, Singapore 4 Division of Medical Oncology, National Cancer Centre, 169610, Singapore 5 Programme in Translational Immunology, Institute for Molecular and Cell Biology 138648, Singapore 6 Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China * The authors contributed equally to these work Correspondence to: Shu Wang, email: dbsws@nus.edu.sg Keywords: peritoneal carcinomatosis, EpCAM, chimeric antigen receptor, T lymphocytes, adoptive immunotherapy Received: June 16, 2016 Accepted: January 03, 2017 Published: January 10, 2017 ABSTRACT The epithelial cell adhesion molecule (EpCAM) is overexpressed in a wide variety of tumor types, including peritoneal carcinomatosis (PC) from gastrointestinal and gynecological malignancies. To develop a chimeric antigen receptor T (CART) cell therapy approach to treat patients with end-stage PC, we constructed third generation CARs specific to EpCAM using the 4D5MOC-B single chain variable fragment. CART cells were generated with lentiviral transduction and exhibited specific in vitro killing activity against EpCAM-positive human ovarian and colorectal cancer cells. A single intraperitoneal injection of the CART cells eradicated established ovarian xenografts and resulted in significantly prolonged animal survival. Since EpCAM is also expressed on normal epithelium, anti-EpCAM CART cells were generated by mRNA electroporation that display a controlled cytolytic activity with a limited CAR expression duration. Multiple repeated infusions of these RNA CAR-modified T cells delayed disease progression in immunodeficient mice bearing well-established peritoneal ovarian and colorectal xenografts. Thus, our study demonstrates the effectiveness of using anti-EpCAM CAR-expressing T cells for local treatment of PC in mice. The possibility of using this approach for clinical treatment of EpCAM-positive gastrointestinal and gynecological malignancies warrants further validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Munz, M., Baeuerle, P. A., & Gires, O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0654 · Cited by 515
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Recent developments in antibody derivatives against colorectal cancer; A review
Ghani, S., Bahrami, S., Rafiee, B., Eyvazi, S., Yarian, F., Ahangarzadeh, S., Khalili, S., Shahzamani, K., Jafarisani, M., Bandehpour, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118791 · Cited by 20
Metadata
- Authors
- Ang, W. X., Li, Z., Chi, Z., Du, S.-H., Chen, C., Tay, J. C. K., Toh, H. C., Connolly, J. E., Xu, X. H., & Wang, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-10
- Volume
- 8
- Issue
- 8
- Pages
- 13545-13559
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2567894773
- Cited by
- 106
- References
- 3
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. https://app.cochat.ai/papers/10.18632/oncotarget.14592
- The paper
- Ang, W. X., Li, Z., Chi, Z., Du, S.-H., Chen, C., Tay, J. C. K., Toh, H. C., Connolly, J. E., Xu, X. H., & Wang, S. (2017). Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. https://doi.org/10.18632/oncotarget.14592
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.